Literature DB >> 2553034

Nedocromil sodium: a review of clinical studies.

F Ruggieri1, F Patalano.   

Abstract

Nedocromil sodium is a new compound for the long-term treatment of bronchial asthma. Its effect has been studied in prevention of bronchospasm induced by a variety of stimuli showing a broader spectrum of activity than SCG. Its clinical efficacy has been demonstrated in a number of trials involving patients regardless of asthma type.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2553034

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN： 0904-1850


  3 in total

Review 1.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

2.  Nedocromil sodium prevents in vivo generation of the eosinophilotactic substance induced by PAF but fails to antagonize its effects.

Authors:  P M e Silva; M A Martins; H C Castro-Faria-Neto; P T Bozza; A L Pires; R S Cordeiro; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

3.  Mast cells and company.

Authors:  Friederike Jönsson; Marc Daëron
Journal:  Front Immunol       Date:  2012-02-20       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.